Table 5. Association with CYP2E1 DraI polymorphism and progression of gastric cancer.

	Total	TT		TA		AA
	No.	No.	%	No.	%	No.	%
Tumor stage
I	41	25	61.0	12	29.3	4	9.7
II	181	122	67.4	38	21.0	21	11.6
III	162	98	60.5	52	32.1	12	7.4
IV	25	15	60.0	7	28	3	12.0
Adjusteda OR (95% CI)
III vs. I		1.00		1.00 (0.45–2.20)		0.90 (0.25–3.17)
III+ IV vs. I		1.00		0.98 (0.45–2.14)		0.93 (0.28–3.11)
III+ IV vs. I+ II		1.00		1.37 (0.86–2.19)		0.75 (0.37–1.52)
Tumor grade
Low	56	39	69.6	11	19.7	6	10.7
Intermediate	116	75	64.7	31	26.7	10	8.6
High	231	171	74.0	34	14.7	26	11.3
Adjusteda OR (95% CI)
Intermediate vs. Low		1.00		1.39 (0.62–3.09)		1.02 (0.33–3.12)
High vs. Low		1.00		0.71 (0.33–1.54)		1.08 (0.41–2.81)

^aAdjusted for sex, age and smoking habit.